-

02:39:27 AM

MNKD Stock News

MNKD - Mannkind Corp

01/24/23 6:00 AM

Nasdaq : MNKD

conferences

MannKind Corporation to Participate in the Lytham Partners Investor Select Conference

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its

RHEA-AI

neutral

01/23/23 6:05 AM

Nasdaq : MNKD

clinical trial

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on clofazimine inhalation suspension demonstrates promising tolerability and

RHEA-AI

neutral

01/05/23 6:00 AM

Nasdaq : MNKD

conferences

MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference

MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief

RHEA-AI

neutral

11/10/22 6:05 AM

Nasdaq : MNKD

conferences

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

Technosphere ® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be

RHEA-AI

neutral

11/08/22 8:00 AM

Nasdaq : MNKD

earnings

MannKind Corporation Reports 2022 Third Quarter Financial Results

Conference Call to Begin Today at 9:00 a.m. (ET) 3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021 3Q 2022 Royalties from Tyvaso DPI of $6.2 million 3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBE

RHEA-AI

neutral

11/01/22 6:00 AM

Nasdaq : MNKD

earnings

MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022

MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM

RHEA-AI

neutral

09/21/22 5:00 PM

Nasdaq : MNKD

conferences

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief

RHEA-AI

neutral

09/06/22 6:15 AM

Nasdaq : MNKD

clinical trial

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE

RHEA-AI

neutral

09/01/22 6:00 AM

Nasdaq : MNKD

conferences

MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief

RHEA-AI

neutral

08/09/22 4:00 PM

Nasdaq : MNKD

earnings

MannKind Corporation Reports 2022 Second Quarter Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI™ approved by the FDA in May representing the second FDA-approved product using the Technosphere ® inhalation platform V-Go ® acquired May 31; $2.1 million Net Revenue recognized for June 2Q 2022 Commercial Products Net Revenue of $12.7

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

MNKD Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.mannkindcorp.com
CeoMichael Castagna
Security nameMannkind Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees241
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address30930 Russell Ranch Rd Ste 300
StateCalifornia
CityWestlake Village
Zip91362-7379
CountryUS
Phone18186615000

About Mannkind Corp

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.